Key Highlights
•
A study found that a reduced dose of the COVID-19 antiviral nirmatrelvir/ritonavir is safe and effective for patients with severe kidney problems who need dialysis. This is crucial because these patients are at very high risk from COVID-19 and standard drug doses can build up to dangerous levels in their bodies.
Source →
•
Researchers discovered that removing a specific brain receptor (NMDA) in mice causes initial problems with brain cell communication, but the brain can partially adapt over time. This helps scientists understand how the brain compensates after injury or disease, which could inform new treatments for brain disorders.
Source →
•
A large European study shows that lung scarring (interstitial lung disease) linked to a specific autoimmune disease (ANCA-associated vasculitis) often has a severe pattern and progresses faster. The drug rituximab may help slow the decline in lung function, highlighting the need for early diagnosis and targeted treatment.
Source →
•
A clinical trial found that adding chemotherapy to a targeted drug (aumolertinib) improves outcomes for lung cancer patients who have both an EGFR mutation and other specific genetic faults. This provides the first evidence that a more aggressive, combination treatment is better for this specific group of patients.
Source →
•
A systematic review concluded that steroid injections may offer short-term pain relief for some children with joint or tendon pain, but the evidence supporting their use is weak and of low quality. This highlights a significant gap in research and the need for better studies to guide safe and effective pain management in kids.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
